Mitral Valve Replacement for Mitral Regurgitation

(CASSINI-US Trial)

This trial tests a new treatment for individuals with moderate to severe mitral regurgitation, a heart condition where the mitral valve fails to close properly, causing blood to flow backward in the heart. The trial evaluates the safety and effectiveness of the SATURN TS TMVR System, a device implanted through a catheter, both immediately after the procedure and over time. Ideal participants are those who experience significant symptoms from mitral regurgitation, can tolerate blood-thinning medication, and face high risks with traditional open-heart surgery. As an unphased trial, this study provides an opportunity to contribute to groundbreaking research and potentially benefit from an innovative treatment.

The trial information does not specify if you need to stop taking your current medications. However, you must be able to tolerate oral anticoagulation, and there should be no known hypersensitivity or contraindication to procedural or post-procedural medication.

In a previous study with the SATURN TS TMVR System, researchers found that 14% of 50 patients passed away within 30 days. The same study showed a 98% success rate for the procedure, indicating correct device implantation in most cases. Another report noted that the SATURN valve performed well and was safe, with patients showing significant improvements in heart valve function after the procedure. However, these results suggest that while the treatment is promising, some risks remain. Prospective participants should consider these findings when deciding to join a trial.¹²³⁴⁵

Most treatments for mitral regurgitation involve surgical options like open-heart surgery or minimally invasive techniques such as percutaneous edge-to-edge repair. However, the SATURN TS TMVR System is unique because it offers a transseptal approach to mitral valve replacement, which is less invasive than traditional surgery. This system allows for valve replacement through a catheter inserted via a small incision, potentially reducing recovery times and surgical risks. Researchers are excited about this treatment because it could provide a safer, more efficient alternative for patients who are high-risk surgical candidates or those who prefer a less invasive procedure.

Research has shown that the SATURN TS TMVR System may help treat mitral regurgitation, a condition where a heart valve fails to close properly, causing blood to leak backward. Participants in this trial will receive the SATURN TMVR System implant. Early results suggest successful placement of this system in patients, leading to improved health outcomes. In initial human trials, the SATURN valve was implanted with positive results, including fewer symptoms and a stable heart valve. Studies indicate that the system is safe and can be inserted using less invasive techniques. While more information is needed, these findings offer promise for those considering this treatment.¹²⁴⁵⁶